Kim Tipton is a Senior Clinical Scientist at ALX Oncology since May 2023, leading phase 2 clinical science initiatives for HNSCC and contributing to solid tumor clinical trials involving evorpacept. Previously, Kim served as Director of Clinical Science at CRISPR Therapeutics, overseeing allogeneic CAR T cell therapies, and held various roles including Associate Director of Clinical Development focused on CD70-directed CAR T therapy. Prior experience includes directing biologics discovery at pH Pharma Inc., leading significant projects at CytomX Therapeutics, and research positions at Catalyst Biosciences and UC Berkeley. Kim holds a PhD in Cellular and Molecular Biology from the University of California, San Francisco, along with a BS in Microbiology and a BA in English Literature from The University of Texas at Austin.
Sign up to view 0 direct reports
Get started
This person is not in any offices